Hybrigenics S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
2,435.00
9,646.00
11,716.00
8,489.00
7,015.00
-
Total Accounts Receivable
3,364.00
3,615.00
5,529.00
716.00
3,754.00
-
Inventories
906.00
262.00
150.00
55.00
-
-
Other Current Assets
80.00
2,188.00
2,189.00
5,788.00
1,902.00
-
Total Current Assets
6,785.00
15,711.00
19,584.00
15,048.00
12,671.00
-
Net Property, Plant & Equipment
241.00
598.00
585.00
326.00
238.00
-
Total Investments and Advances
95.00
-
-
-
101.00
-
Long-Term Note Receivable
-
-
121.00
68.00
64.00
-
Intangible Assets
532.00
1,023.00
820.00
524.00
518.00
-
Other Assets
265.00
216.00
192.00
216.00
381.00
-
Total Assets
7,918.00
17,548.00
21,302.00
16,182.00
13,973.00
-
ST Debt & Current Portion LT Debt
178.00
862.00
288.00
91.00
97.00
Accounts Payable
1,145.00
2,076.00
1,727.00
1,565.00
2,409.00
Income Tax Payable
391.00
345.00
353.00
117.00
374.00
Other Current Liabilities
1,982.00
2,016.00
2,329.00
3,181.00
1,629.00
Total Current Liabilities
3,696.00
5,299.00
4,697.00
4,954.00
4,509.00
Long-Term Debt
321.00
182.00
114.00
-
-
Provision for Risks & Charges
303.00
473.00
515.00
346.00
305.00
Total Liabilities
4,320.00
5,954.00
5,326.00
5,300.00
4,814.00
Common Equity (Total)
2,411.00
11,557.00
15,903.00
10,804.00
9,159.00
Total Shareholders' Equity
2,411.00
11,557.00
15,903.00
10,804.00
9,159.00
Total Equity
2,447.00
11,594.00
15,976.00
10,882.00
9,159.00
Liabilities & Shareholders' Equity
7,918.00
17,548.00
21,302.00
16,182.00
13,973.00
Accumulated Minority Interest
36.00
37.00
73.00
78.00
-
Non-Equity Reserves
1,151.00
-
-
-
-

About Hybrigenics

View Profile
Address
3-5, impasse Reille
Paris Ile-de-France 75014
France
Employees -
Website http://www.hybrigenics.com
Updated 07/08/2019
Hybrigenics SA operates as a biopharmaceutical company, which engages in the research and development of targets and therapies against proliferative diseases. It develops inecalcitol for the treatment of prostate cancer, chronic lymphocytic leukemia, and chronic myeloid leukemia. The company was founded on December 29, 1997 and is headquartered in Paris, France.